CDK inhibitors as potential breast cancer therapeutics: new evidence for enhanced efficacy in ER(+ )disease

Loss of cell cycle control is a hallmark of cancer, and aberrations in the cyclin-CDK-RB (cyclin-dependent kinase-retinoblastoma protein) pathway are common in breast cancer. Consequently, inhibition of this pathway is an attractive therapeutic strategy, but results from clinical trials of CDK inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Sutherland, Robert L, Musgrove, Elizabeth A
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2815549/
https://www.ncbi.nlm.nih.gov/pubmed/20067604
http://dx.doi.org/10.1186/bcr2454

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2815549/
https://www.ncbi.nlm.nih.gov/pubmed/20067604
http://dx.doi.org/10.1186/bcr2454

Ejemplares similares